Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.35
-$0.44-55.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 33.60% | 31.07% | 24.68% | 27.42% | 23.79% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 134.37% | 241.77% | 243.35% | -47.30% | -75.01% |
| Change in Net Operating Assets | -51.36% | -661.28% | -1,267.74% | -169.97% | -162.30% |
| Cash from Operations | 26.68% | 16.28% | 24.70% | 6.50% | -18.43% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -58.35% | 35.40% | 35.40% | 35.40% | 46.35% |
| Total Debt Repaid | 11.68% | -16.32% | -52.63% | 10.77% | 22.28% |
| Issuance of Common Stock | 10.41% | 4.58% | 1.75% | -29.31% | -30.08% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 8.05% | 4.76% | 1.49% | -28.91% | -28.70% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 109.73% | 1,199.98% | 184.16% | -1,030.83% | -304.04% |